RMi pre-open: Reaction

October 30, 2025 7:56am

To the “rate” decision after “Jerome’s” raison d’etre with the Fed’s division on display re a December rate cut is "far from" a forgone conclusion

Price uncertainty and earnings releases could provide traders with attractive buying opportunity after a big dive

Earnings: Analym Pharmaceuticals (ALNY)

Pre-open Signals: 3 Positive and 4 Negative Indications

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

Keep your ears slapping and our eyes on the news/computer about meeting between Trump and China's Xi. Will it strengthen ongoing trade?

Wednesday night’s … RMi Closing Bell: Optimism fades … https://www.regmedinvestors.com/articles/14173

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

Wednesday: The pre-open Dow futures are DOWN -0.32% or (-154 points), the S&P futures are DOWN -0.30% or (-21 points) and the Nasdaq futures are DOWN -0.47% or (-223 points)

• Stock futures are in lower territory, Thursday 10/30
• European markets were residing negative territory,
• Asia Pacific markets were mixed

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

• Wednesday: The Dow closed DOWN -74.37 points or -0.16%, the S&P closed DOWN -0.30 points or -0.00% while the Nasdaq closed UP +139.98 points or +0.55%
• Tuesday: The Dow closed UP +161.78 points or +0.34%, the S&P closed UP +15.76 points or +0.23% while the Nasdaq closed UP +190.037 points or +0.80%
• Monday: The Dow closed UP +337.47 points or +0.71%, the S&P closed UP +83.47 points or +1.23% while the Nasdaq closed UP +432.589 points or +1.86%
• Week to date: The S&P 500 is up 1.5%, the Dow +0.9% and the Nasdaq is up +3.2%.
• Last week: the S&P 500 was up +2%, the Dow +2% and the Nasdaq added +2%.
• The previous week: the S&P 500 was up +1.7%, the Dow +1.6% and the Nasdaq +2.1%.
• Last month and Q3’s numbers, the S&P 500 Q was up +7% and the month -4.2%, the Nasdaq’s Q is up +11% and the month +5% while the Dow’s Q is up +5% and the month +1%

Q4 – 1 neutral, 9 positive and 11 negative closes

• Q3 – September, 1 holiday, 9 negative and 12 positive closes; August - 11 negative and 9 positive closes; July – 1 market holiday, 13 positive and 9 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

• October began with a government shutdown and much fewer econs… along with the usual ups, downs
• Now uncertainty rules

Info:

Alnylam Pharmaceuticals (ALNY) closed up +$5.68 after Tuesday’s -$2.67 and Monday’s +$15.15 with a positive +$8.41 or +1.75% pre-open

MiMedx (MDXG) closed up +$0.31 and Tuesday’s +$0.15 with a positive +$0.61 or +8.48% pre-open

Vertex (VRTX) closed down -$5.18, Tuesday’s +$2.22 after Monday’s -$1.22 with a negative -$0.83 or -0.20% pre-open

BioNTech (BNTX) closed down -$1.68 after Tuesday’s -$1.02 and Monday’s +$0.39 with a positive +$0.84 or +0.81% pre-open

CRISPR Therapeutics (CRSP) closed down -$1.61 after Tuesday’s -$1.55 and Monday’s -$1.89 with a negative -$0.18 or -0.29% pre-open

Intellia Therapeutics (NTLA0 closed down -$0.84 after Tuesday’s -$0.83 and Monday’s -$10.81 with a negative -$2.05 or -15.63% pre-open

Sarepta Therapeutics (SRPT) closed down -$0.77 after Tuesday’s +$0.72 and Monday’s +$0.69 with a negative -$0.10 or -0.43% pre-open

The BOTTOM LINE: I got on my computer/laptop/ my horse with a lantern as I ride yelling … “earnings are here, earnings are here”!

Q3 Earnings are in the front-view mirror this week … more coming

• Vertex (VRTX) and Sarepta Therapeutics (SUPN) on 11/3, Ultragenyx Pharmaceuticals (RARE), Supernus Therapeutics (SUPN) on 11/4 followed by Regenxbio (RGNX), Moderna (MRNA) and Vericel (VCEL)

Expect earnings’ results that meet, beat or miss revenue estimates, EPS as to pricing expectations, consensus … sector earnings while LPS (loss-per-share) assumes adjustments

• As sector earnings meet, beat or miss expectations; whipsaw actions could ensue depreciations or the stock market heads south, back pedal -- fast.

Upcoming;

• Sarepta Therapeutics (SRPT) is soon to post loss of $0.03 per share forQ3/25. This estimate indicates a year-over-year change of -104.8%. This Q3's revenue is expected to be $346.23 million, down 25.9% from the year-ago quarter.
• Ultragenyx Pharmaceuticals (RARE) is expected to post a Q3 loss of $0.85 per share which represents a year-over-year change of +6.6%. Revenues are expected to be $6.93 million, up 202.6% from the year-ago quarter
• uniQure NV (QURE) is expected to post quarterly loss of $0.85 per share in its upcoming report, which represents a year-over-year change of +6.6%Revenues are expected to be $6.93 million, up 202.6% from the year-ago quarter.

The shutdown enters its 29^th day today, with lawmakers still unable to agree on a funding bill … as Democrats block the 13th voting negotiation

Welcome to my world of defining the “grey’ in our universe!

• “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

October: understand the new “flow” …

New week:

• 10/29 - Wednesday closed negative with 9 positive, 30 negative and 1 flat
• 10/28 -Tuesday closed negative with 16 positive, 21 negative and 3 flats
• 10/27- Monday closed negative with 18 positive, 22 negative and 0 flats

Last week:

• 10/24 - Friday closed positive with 25 positive, 13 negative and 2 flats
• 10/23 – Thursday closed negative with 15 negative, 22 negative and 3 flats
• 10/22 – Wednesday closed negative with 4 positive, 34 negative and 2 flat
• 10/21 - Tuesday closed negative with 17 positive, 23 negative and 0 flat
• 10/20 - Monday closed positive with 34 positive, 4 negative and 2 flats

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.